Estrogen Receptor-Alpha, Breast Cancer Patients And Tamoxifen Response

Researchers have found evidence of a statistically significant survival benefit from adjuvant tamoxifen among patients whose estrogen receptor (ER)-positive tumors had high levels of phosphorylation of ER-alpha; at serine-118 (ER-alpha S118-P), according to a brief communication published online November 25 in the Journal of the National Cancer Institute. Approximately 50% of breast carcinomas are resistant to tamoxifen.

source : www.medicalnewstoday.com

Related News:

• SGO: New Option for Recurrent Ovarian Cancer?
• Accelerating The Pace Of Discovery In Cancer Research
• SGO: New Option for Recurrent Ovarian Cancer? (CME/CE)
• Impact Of Ethnicity On Primary Treatment Choice And Mortality In Men With Prostate Cancer: Data From CaPSURE
• Gaps Remain in Cancer Palliative Care (CME/CE)
• Cordyceps mushroom is an effective cancer treatment, states new research
• Insufficiency Fractures After Pelvic Radiotherapy In Patients With Prostate Cancer
• Genetic variations influence statin efficacy for lowering colon cancer risk
• Heart transplant patients face greater risk of skin cancer
• How Cells Protect Themselves From Cancer